You are here: Industry Insights > GlaxoSmithKline

News List

GlaxoSmithKline bids adieu to vaccines President Luc Debruyne as executive overhaul continues fiercevaccines
June 26, 2018
GlaxoSmithKline has experienced multiple top executive departures under CEO Emma Walmsley, but the reformation of the company's leadership isn't finished yet.
GlaxoSmithKline to pass $10B in 2024 vaccine sales, with Merck, Sanofi and Pfizer rounding out the top 4: report fiercevaccines
June 26, 2018
Shingrix may not make it on the top five best-selling vaccines list in 2024, but a diversified portfolio will still secure GlaxoSmithKline the lead position in the vaccine industry at that time, followed by Merck &Co.,
GlaxoSmithKline to pass $10B in 2024 vaccine sales, with Merck, Sanofi and Pfizer rounding out the top 4: report fiercepharma
June 13, 2018
Shingrix may not make it on the top 5 best-selling vaccines list in 2024...
GlaxoSmithKline boosted Shingrix educational efforts after seeing administration, storage errors in launch fiercepharma
June 06, 2018
Drug launches come with an array of challenges, and GlaxoSmithKline is experiencing that firsthand with its U.S. shingles vaccine rollout.
GlaxoSmithKline veteran Zhi Hong launches Brii Biosciences with $260M fiercebiotech
May 29, 2018
Zhi Hong, an 11-year veteran of GlaxoSmithKline, is striking out on his own with a startup geared to improve public health in China.
GlaxoSmithKline's next-generation HIV battle against Gilead is already taking a toll on growth fiercepharma
April 28, 2018
GlaxoSmithKline execs touted their HIV growth drive this week, pointing to next-generation medications Triumeq and Tivicay as the fuel.But both drugs actually fell short of analyst forecasts...
First-quarter sales of GlaxoSmithKline's prescription drugs fall 4 percent firstwordpharma
April 26, 2018
GlaxoSmithKline said Wednesday that first-quarter revenue from prescription drugs slipped 4 percent year-over-year to 4 billion pounds , hit by currency effects and lower sales of Seretide/Advair, Ventolin and established medicines.
Editorial questions study design supporting effectiveness of GlaxoSmithKline, Innoviva's Trelegy Ellipta triple therapy for COPD firstwordpharma
April 20, 2018
An editorial published in the NEJM alongside detailed results from the IMPACT study of GlaxoSmithKline and Innoviva's once-daily single inhaler triple therapy Trelegy Ellipta
GSK Recruiting Score: Genentech's Kevin Sin to Help Drive R&D and M&A biospace
April 19, 2018
GlaxoSmithKline Chief Executive Officer Emma Walmsley continues to hone her leadership team with a hire who will focus on potential research and development deals.
After Spurning Pfizer GlaxoSmithKline Cuts $13B Deal with Novartis biospace
March 28, 2018
GlaxoSmithKline walked away from a potential deal to acquire Pfizer’s consumer health unit four days ago and instead opted to invest in its own consumer unit.

Previous page 1 2 3 4 5 6 7 8 9 10 11 Next page